课件：阴性乳腺癌新辅助治疗.ppt

后面内容直接删除就行 资料可以编辑修改使用 资料可以编辑修改使用 资料仅供参考，实际情况实际分析 主要经营：课件设计，文档制作，网络软件设计、图文设计制作、发布广告等 秉着以优质的服务对待每一位客户，做到让客户满意！ 致力于数据挖掘，合同简历、论文写作、PPT设计、计划书、策划案、学习课件、各类模板等方方面面，打造全网一站式需求 * * 尽管三阴性乳腺癌仅占总体15%，但这中乳腺癌是最令我们医生头痛的，因为至今为止，我们对三阴性乳腺癌的发病机制并不十分清楚，这种肿瘤的异质性。 * * * 以下治疗特性与pCR提升率相关: 提高化疗周期次数 高剂量(vs 低剂量)蒽环霉素或紫杉醇 在治疗方案中加入希罗达 在治疗方案中加入赫赛汀(对HER2阳性患者) von Minckwitz et al. ASCO 2010 (Abst 501). * * * * Berton-Rigaud D et al. J Clin Oncol 2008;26(15S):598. Benefit of neoadjuvant capecitabine + epirubicin + cyclophosphamide (CEX) vs 5-FU + epirubicin + cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T) Berton-Rigaud D, Roché H, Penault-Llorca F, Tubiana-Mathieu N, Ferrero JM, Coudert B, Milano G, Mousseau M, Homokos H, Fumoleau P. Background: A phase II trial was conducted to show non-inferiority of neoadjuvant CEX vs FEC. Methods: 182 patients (pts) with operable BC (T2–3, N0–1) were randomized (1:1) to four 3-weekly cycles of CEX (X 900 mg/m2 bid d1–14, E 100 mg/m2 d1, C 500 mg/m2 d1; n=94) or FEC (5-FU 500 mg/m2, E and C as above; n=88). Pts underwent surgery 4–6 weeks after the 4th cycle, followed by 4 adjuvant cycles of 3-weekly T 100 mg/m2. Primary endpoint was pCR rate (Sataloff criteria). Results: Baseline characteristics were well balanced. All 4 neoadjuvant cycles were given in 95% of CEX and 97% of FEC pts. Median dose intensity was 95% for X and 99% for 5-FU. The primary objective was met: CEX was non-inferior to FEC (Table). Clinical overall response rate was 58% with CEX vs 54% with FEC. Clinical CR occurred in 12% vs 5%, respectively. During neoadjuvant therapy, treatment-related G3/4 AEs occurred in 59% and 65% of pts, respectively. CEX was associated with more treatment-related G3/4 mucositis (6% vs 1%) and less G3/4 nausea/vomiting (11% vs 28%). Median adjuvant T dose intensity was 99% and 100%, respectively. Adjuvant T was well tolerated: treatment-related G3/4 AEs occurred in 5% and 6% of pts receiving CEX and FEC, respectivel